Shin‐ichi Harashima

Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial

Christopher Sorli, Shin‐ichi Harashima, George Tsoukas et al. · The Lancet Diabetes & Endocrinology · 2017 · 707 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Mechanisms for cytotoxic effects of anti–tumor necrosis factor agents on transmembrane tumor necrosis factor α–expressing cells: Comparison among infliximab, etanercept, and adalimumab

Hiroki Mitoma, Takahiko Horiuchi, Hiroshi Tsukamoto et al. · Arthritis & Rheumatism · 2008 · 345 citations

Medicine, Immunology, Pharmacology +17

Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-α

Hiroki Mitoma, Takahiko Horiuchi, Nobuaki Hatta et al. · Gastroenterology · 2005 · 268 citations · Full text

Life Sciences, Immunology, Pharmacology +17

Outside-to-Inside Signal Through the Membrane TNF-α Induces E-Selectin (CD62E) Expression on Activated Human CD4+ T Cells

Shin‐ichi Harashima, Takahiko Horiuchi, Nobuaki Hatta et al. · The Journal of Immunology · 2001 · 131 citations · Full text

Life Sciences, Cell Biology, Immunology +12

Association of tumor necrosis factor receptor type II polymorphism 196R with systemic lupus erythematosus in the Japanese: Molecular and functional analysis

Chika Morita, Takahiko Horiuchi, Hiroshi Tsukamoto et al. · Arthritis & Rheumatism · 2001 · 128 citations

Life Sciences, Genetics, Molecular Genetics +15